Clinical Trials
75 trialsDasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
VASCATAQ
University Hospital, Rouen
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Carboplatin and Bevacizumab for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
University of Utah
A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers
Qilu Pharmaceutical Co., Ltd.
TASCO1
Servier
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Servier
CITRINO
Tesaro, Inc.
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
CanStem303C
Sumitomo Pharma America, Inc.
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
AbbVie
AVANA
Centus Biotherapeutics Limited
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Cedars-Sinai Medical Center
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Hoffmann-La Roche
BEV-ONCO2012
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
Circadian Technologies Ltd.
ReACT
Celldex Therapeutics
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®
R-Pharm
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Oncolytics Biotech
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Amgen
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
University of Pittsburgh
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
Lipomedix Pharmaceuticals Inc.
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ohio State University Comprehensive Cancer Center
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
National Institutes of Health Clinical Center (CC)
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
Genentech, Inc.
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
DOUBLIRI
GERCOR - Multidisciplinary Oncology Cooperative Group
Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer
Hellenic Oncology Research Group
Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer
Hellenic Oncology Research Group
RADBEV
University of Pittsburgh
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Progen Pharmaceuticals
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
University of Pittsburgh
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Massachusetts General Hospital
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
Boehringer Ingelheim